Johns Hopkins Tolerogenic Antigen-Presenting Cell Patent US12605463B2
Summary
The USPTO granted patent US12605463B2 to Johns Hopkins University covering biodegradable particles designed to interact with immune cells and generate immunosuppressive effects. The particles include a polyester or polyester blend with soluble protein or small molecule encapsulated within, and two surface-attached protein types acting as Signal 1 and Signal 2 for immune cell binding and co-stimulation. The invention claims methods for inducing regulatory T cells and treating autoimmune diseases.
What changed
USPTO granted patent US12605463B2 to Johns Hopkins University for biodegradable particles interacting with immune cells to generate immunosuppressive effects. The particles comprise a polyester or polyester blend with encapsulated protein and two surface-attached protein types acting as immune cell signals. The patent covers methods of use for inducing regulatory T cells and treating autoimmune diseases.\n\nFor researchers and companies developing tolerogenic particle technologies for autoimmune disease treatment, this patent defines intellectual property boundaries. Parties should conduct freedom-to-operate analyses and evaluate whether their technologies fall within the patent's scope or qualify for research use exemptions.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Tolerogenic artificial antigen-presenting cells
Grant US12605463B2 Kind: B2 Apr 21, 2026
Assignee
The Johns Hopkins University
Inventors
Jordan J. Green, Kelly Rhodes, Randall A. Meyer, Stephany Yi Tzeng
Abstract
Biodegradable particles for interacting with immune cells to generate an immunosuppressive effect are disclosed. The biodegradable particle comprises a polyester or polyester blend with at least one soluble protein or small molecule encapsulated within the particle and at least two types of protein attached to a surface of the particle or to a coating on the surface thereof, which can be used to induce targeting regulatory T cells (Tregs). The at least two types of protein attached to a surface of the particle or to a coating on the surface thereof include a “Signal 1” protein that binds to an immune cell and a “Signal 2” protein that acts as a co-stimulatory molecule to immune cells. The encapsulated protein can be an interleukin and/or a cytokine. Methods of their use for treating a disease or condition, including an autoimmune disease, are disclosed.
CPC Classifications
A61K 47/6937 A61K 47/6425 A61K 47/646 A61K 47/6849 A61K 31/436 A61K 38/1841 A61K 39/0008 A61P 37/06
Filing Date
2020-06-12
Application No.
17602932
Claims
23
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.